

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2011

Vol. 39, No. 9

## CONTENTS

### ARTICLES

- Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences. *Weirong Wang, Ping Lu, Yulin Fang, Lora Hamuro, Tamara Pittman, Brian Carr, Jerome Hochman, and Thomayant Prueksaritanont* . . . . . **1469**
- pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein. *Li Li, Yuk Yin Sham, Zsolt Bikadi, and William F. Elmquist* . . . . . **1478**
- Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation. *Ana I. Loureiro, Carlos Fernandes-Lopes, Maria J. Bonifácio, Lyndon C. Wright, and Patricio Soares-da-Silva* . . . . . **1486**
- Impact of Intestinal Glucuronidation on the Pharmacokinetics of Raloxifene. *Keigo Kosaka, Norifumi Sakai, Yuya Endo, Yuga Fukuhara, Minoru Tsuda-Tsukimoto, Tatsuyuki Ohtsuka, Ichiro Kino, Tomohiko Tanimoto, Naomi Takeba, Masakatsu Takahashi, and Toshiyuki Kume* . . . . . **1495**
- Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes. *Naoki Kotani, Kazuya Maeda, Takao Watanabe, Mariko Hiramatsu, Likun Gong, Yi-an Bi, Toshiaki Takezawa, Hiroyuki Kusuhara, and Yuichi Sugiyama* . . . . . **1503**
- Bioactivation of Glafenine by Human Liver Microsomes and Peroxidases: Identification of Electrophilic Iminoquinone Species and GSH Conjugates. *Bo Wen and David J. Moore* . . . . . **1511**
- Inhibitory Effects of Commonly Used Herbal Extracts on UDP-Glucuronosyltransferase 1A4, 1A6, and 1A9 Enzyme Activities. *Mohamed-Eslam F. Mohamed and Reginald F. Frye* . . . . . **1522**
- Ocular Pharmacokinetics of Dorzolamide and Brinzolamide After Single and Multiple Topical Dosing: Implications for Effects on Ocular Blood Flow. *Rajendra S. Kadam, Gajanan Jadhav, Miller Ogidigen, and Uday B. Kompella* . . . . . **1529**
- Sequential Metabolism of Sesamin by Cytochrome P450 and UDP-Glucuronosyltransferase in Human Liver. *Kaori Yasuda, Shinichi Ikushiro, Masaki Kamakura, Eiji Munetsuna, Miho Ohta, and Toshiyuki Sakaki* . . . . . **1538**
- Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate. *Brooke M. VandenBrink, Robert S. Foti, Dan A. Rock, Larry C. Wienkers, and Jan L. Wahlstrom* . . . . . **1546**
- Disposition and Metabolism of Ticagrelor, a Novel P2Y<sub>12</sub> Receptor Antagonist, in Mice, Rats, and Marmosets. *Yan Li, Claire Landqvist, and Scott W. Grimm* . . . . . **1555**
- Efficient Screening of Cytochrome P450 BM3 Mutants for Their Metabolic Activity and Diversity toward a Wide Set of Drug-Like Molecules in Chemical Space. *Jelle Reinen, Jolanda S. van Leeuwen, Yongmin Li, Lifang Sun, Peter D. J. Grootenhuis, Caroline J. Decker, John Saunders, Nico P. E. Vermeulen, and Jan N. M. Commandeur* . . . . . **1568**
- Production of 22-Hydroxy Metabolites of Vitamin D<sub>3</sub> by Cytochrome P450scc (CYP11A1) and Analysis of Their Biological Activities on Skin Cells. *Robert C. Tuckey, Wei Li, Haleem Z. Shehabi,*

Continued on next page

	<i>Zorica Janjetovic, Minh N. Nguyen, Tae-Kang Kim, Jianjun Chen, Danielle E. Howell, Heather A. E. Benson, Trevor Sweatman, Donna M. Baldisseri, and Andrzej Slominski</i> . . . . .	<b>1577</b>
☐	Preclinical Disposition (In Vitro) of Novel $\mu$ -Opioid Receptor Selective Antagonists. <i>Pallabi Mitra, Jürgen Venitz, Yunyun Yuan, Yan Zhang, and Phillip M. Gerk</i> . . . . .	<b>1589</b>
☐	From Single Compounds to Herbal Extract: A Strategy to Systematically Characterize the Metabolites of Licorice in Rats. <i>Cheng Xiang, Xue Qiao, Qing Wang, Rui Li, Wenjuan Miao, Dean Guo, and Min Ye</i> . . . . .	<b>1597</b>
	Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus. <i>Amit S. Kalgutkar, Meera Tugnait, Tong Zhu, Emi Kimoto, Zhuang Miao, Vincent Mascitti, Xin Yang, Beijing Tan, Robert L. Walsky, Jonathan Chupka, Bo Feng, and Ralph P. Robinson</i> . . . . .	<b>1609</b>
	Metabolism of [ <sup>14</sup> C]GSK977779 in Rats and Its Implication with the Observed Covalent Binding. <i>Catherine D. Tsalta, Armina Madatian, Ernest M. Schubert, Fangming Xia, William M. Hardisty, Yanli Deng, Jennifer L. Seymour, and Peter D. Gorycki</i> . . . . .	<b>1620</b>
☐	Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction. <i>Michael Gertz, J. Brian Houston, and Aleksandra Galetin</i> . . . . .	<b>1633</b>
	Oral Absorption of Clarithromycin Is Nearly Abolished by Chronic Comedication of Rifampicin in Foals. <i>Jette Peters, Wiebke Block, Stefan Oswald, Johanna Freyer, Markus Grube, Heyo K. Kromer, Marc Lämmer, Dieter Lütjohann, Monica Venner, and Werner Siegmund</i> . . . . .	<b>1643</b>
	<i>UGT1A6</i> and <i>UGT2B15</i> Polymorphisms and Acetaminophen Conjugation in Response to a Randomized, Controlled Diet of Select Fruits and Vegetables. <i>Sandi L. Navarro, Yu Chen, Lin Li, Shuying S. Li, Jyh-Lurn Chang, Yvonne Schwarz, Irena B. King, John D. Potter, Jeannette Bigler, and Johanna W. Lampe</i> . . . . .	<b>1650</b>
☐	In Vitro Characterization of the Metabolic Pathways and Cytochrome P450 Inhibition and Induction Potential of BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor. <i>Hai-zheng Hong, Hong Su, Li Ma, Ming Yao, Ramaswamy A. Iyer, W. Griffith Humphreys, and Lisa J. Christopher</i> . . . . .	<b>1658</b>
	A Novel Biotransformation of Alkyl Aminopyrrolidine to Aminopiperidine Ring by Human CYP3A. <i>Yuping Chen, Gary L. Skiles, Magang Shou, Dean Hickman, and Faye Hsieh</i> . . . . .	<b>1668</b>
	1-Aminobenzotriazole, a Known Cytochrome P450 Inhibitor, Is a Substrate and Inhibitor of <i>N</i> -Acetyltransferase. <i>Q. Sun, T. W. Harper, E. A. Dierks, L. Zhang, S. Chang, A. D. Rodrigues, and P. Marathe</i> . . . . .	<b>1674</b>
☐	Colonic Catabolism of Ellagitannins, Ellagic Acid, and Raspberry Anthocyanins: In Vivo and In Vitro Studies. <i>Rocío González-Barrio, Christine A. Edwards, and Alan Crozier</i> . . . . .	<b>1680</b>
	Paracetamol-Induced Hypothermia Is Independent of Cannabinoids and Transient Receptor Potential Vanilloid-1 and Is Not Mediated by AM404. <i>Samir S. Ayoub, Gareth Pryce, Michael P. Seed, Christopher Bolton, Roderick J. Flower, and David Baker</i> . . . . .	<b>1689</b>
	Novel Pathway of Metabolic Activation of Bisphenol A-Related Compounds for Estrogenic Activity. <i>Katsuhiro Okuda, Tomoko Fukuuchi, Masufumi Takiguchi, and Shin'ichi Yoshihara</i> . . . . .	<b>1696</b>
	Interaction of <i>N</i> -(2-Hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates with Human Liver Microsomal Cytochromes P450: Comparison with Free Doxorubicin. <i>Vlastimil Mašek, Eva Anzenbacherová, Tomáš Etrych, Jiří Strohalm, Karel Ulbrich, and Pavel Anzenbacher</i> . . . . .	<b>1704</b>
	Application of the Fluorescent Probe 1-Anilino-naphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes. <i>James A. McLure, Donald J. Birkett, David J. Elliot, J. Andrew Williams, Andrew Rowland, and John O. Miners</i> . . . . .	<b>1711</b>
	Gestation Time-Dependent Pharmacokinetics of Intravenous (+)-Methamphetamine in Rats. <i>Sarah White, Elizabeth Laurenzana, Howard Hendrickson, W. Brooks Gentry, and S. Michael Owens</i> . . . . .	<b>1718</b>
	Metabolism of Methylisoeugenol in Liver Microsomes of Human, Rat, and Bovine Origin. <i>Alexander T. Cartus, Karl-Heinz Merz, and Dieter Schrenk</i> . . . . .	<b>1727</b>
☐	Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects. <i>Yanli Deng, Armina Madatian, Mary Beth Wire, Carolyn Bowen, Jung Wook Park, Daphne Williams, Bin Peng, Ernest Schubert, Frances Gorycki, Mark Levy, and Peter D. Gorycki</i> . . . . .	<b>1734</b>
	Investigations of Hydrazine Cleavage of Eltrombopag in Humans. <i>Yanli Deng, Martin Rogers, Caroline Sychterz, Kimberly Talley, Yanwen Qian, David Bershas, May Ho, Wei Shi, Emile P. Chen, Cosette Serabjit-Singh, and Peter D. Gorycki</i> . . . . .	<b>1747</b>
	Characterization of the Inhibitory Effects of <i>N</i> -Butylpyridinium Chloride and Structurally Related Ionic Liq-	

Contents (cont'd.)

- uoids on Organic Cation Transporters 1/2 and Human Toxic Extrusion Transporters 1/2-K In Vitro and In Vivo. *Yaofeng Cheng, Lucy J. Martinez-Guerrero, Stephen H. Wright, Robert K. Kuester, Michelle J. Hooth, and I. Glenn Sipes* . . . . . **1755**
- Metabolism and Disposition of Isoflavone Conjugated Metabolites in Humans after Ingestion of Kinako. *Kaori Hosoda, Takashi Furuta, and Kazuo Ishii* . . . . . **1762**
- In Vitro Metabolism of the Mycotoxin Enniatin B in Different Species and Cytochrome P450 Enzyme Phenotyping by Chemical Inhibitors. *Christiane K. Fæste, Lada Ivanova, and Silvio Uhlig* . . . . . **1768**

**ERRATUM**

- Correction to “A Refined Cytochrome P540 IC<sub>50</sub> Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors” . . . . . **1777**

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* (A) homology model of BCRP, (B) PMX, (C) BCRP recognition site for PMX transport. See the article by Li et al. on page 1478 of this issue.